Mixed influenza A and B infections complicate the detection of influenza viruses with altered sensitivities to neuraminidase inhibitors.
Identifieur interne : 000648 ( Ncbi/Merge ); précédent : 000647; suivant : 000649Mixed influenza A and B infections complicate the detection of influenza viruses with altered sensitivities to neuraminidase inhibitors.
Auteurs : Peter G. Mohr [Australie] ; Henriette Geyer ; Jennifer L. Mckimm-BreschkinSource :
- Antiviral research [ 1872-9096 ] ; 2011.
Descripteurs français
- KwdFr :
- Animaux, Antienzymes (pharmacologie), Antienzymes (usage thérapeutique), Antiviraux (pharmacologie), Antiviraux (usage thérapeutique), Chiens, Grippe humaine (diagnostic), Grippe humaine (sang), Grippe humaine (virologie), Humains, Lignée cellulaire, Oséltamivir (pharmacologie), Oséltamivir (usage thérapeutique), Résistance virale aux médicaments, Sialidase (antagonistes et inhibiteurs), Sous-type H2N2 du virus de la grippe A (isolement et purification), Virus influenza B (isolement et purification), Zanamivir (pharmacologie), Zanamivir (usage thérapeutique).
- MESH :
- antagonistes et inhibiteurs : Sialidase.
- diagnostic : Grippe humaine.
- isolement et purification : Sous-type H2N2 du virus de la grippe A, Virus influenza B.
- pharmacologie : Antienzymes, Antiviraux, Oséltamivir, Zanamivir.
- sang : Grippe humaine.
- usage thérapeutique : Antienzymes, Antiviraux, Oséltamivir, Zanamivir.
- virologie : Grippe humaine.
- Animaux, Chiens, Humains, Lignée cellulaire, Résistance virale aux médicaments.
English descriptors
- KwdEn :
- Animals, Antiviral Agents (pharmacology), Antiviral Agents (therapeutic use), Cell Line, Dogs, Drug Resistance, Viral, Enzyme Inhibitors (pharmacology), Enzyme Inhibitors (therapeutic use), Humans, Influenza A Virus, H2N2 Subtype (isolation & purification), Influenza B virus (isolation & purification), Influenza, Human (blood), Influenza, Human (diagnosis), Influenza, Human (virology), Neuraminidase (antagonists & inhibitors), Oseltamivir (pharmacology), Oseltamivir (therapeutic use), Zanamivir (pharmacology), Zanamivir (therapeutic use).
- MESH :
- chemical , antagonists & inhibitors : Neuraminidase.
- chemical , pharmacology : Antiviral Agents, Enzyme Inhibitors, Oseltamivir, Zanamivir.
- chemical , therapeutic use : Antiviral Agents, Enzyme Inhibitors, Oseltamivir, Zanamivir.
- blood : Influenza, Human.
- diagnosis : Influenza, Human.
- isolation & purification : Influenza A Virus, H2N2 Subtype, Influenza B virus.
- virology : Influenza, Human.
- Animals, Cell Line, Dogs, Drug Resistance, Viral, Humans.
Abstract
Previously, three influenza A(H3N2) isolates with a reduced susceptibility to the neuraminidase inhibitors (NAIs) zanamivir and oseltamivir were identified during screening by the Neuraminidase Inhibitor Susceptibility Network (NISN). The isolates were from untreated patients from the first three years post licensure of the NAIs. We plaque-purified progeny from each of these isolates and determined the NAI sensitivity of each plaqued population. Sequencing and serology for each population revealed that the isolates contained a mix of wild type influenza A(H3N2) and influenza B. The NAI susceptibility reductions that had originally been reported were a consequence of influenza B neuraminidases that have lower relative NAI sensitivities, rather than being due to resistant influenza A(H3N2) viruses. Our study highlights the need to check for mixed influenza infections when isolates with potentially lower sensitivities to NAIs are identified.
DOI: 10.1016/j.antiviral.2011.04.010
PubMed: 21549758
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000172
- to stream PubMed, to step Curation: 000172
- to stream PubMed, to step Checkpoint: 000151
Links to Exploration step
pubmed:21549758Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Mixed influenza A and B infections complicate the detection of influenza viruses with altered sensitivities to neuraminidase inhibitors.</title><author><name sortKey="Mohr, Peter G" sort="Mohr, Peter G" uniqKey="Mohr P" first="Peter G" last="Mohr">Peter G. Mohr</name><affiliation wicri:level="1"><nlm:affiliation>CSIRO Livestock Industries, Australian Animal Health Laboratory (AAHL), Private Bag, Geelong VIC, Australia. peter.mohr@csiro.au</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>CSIRO Livestock Industries, Australian Animal Health Laboratory (AAHL), Private Bag, Geelong VIC</wicri:regionArea><wicri:noRegion>Geelong VIC</wicri:noRegion></affiliation></author><author><name sortKey="Geyer, Henriette" sort="Geyer, Henriette" uniqKey="Geyer H" first="Henriette" last="Geyer">Henriette Geyer</name></author><author><name sortKey="Mckimm Breschkin, Jennifer L" sort="Mckimm Breschkin, Jennifer L" uniqKey="Mckimm Breschkin J" first="Jennifer L" last="Mckimm-Breschkin">Jennifer L. Mckimm-Breschkin</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2011">2011</date><idno type="RBID">pubmed:21549758</idno><idno type="pmid">21549758</idno><idno type="doi">10.1016/j.antiviral.2011.04.010</idno><idno type="wicri:Area/PubMed/Corpus">000172</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000172</idno><idno type="wicri:Area/PubMed/Curation">000172</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000172</idno><idno type="wicri:Area/PubMed/Checkpoint">000151</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000151</idno><idno type="wicri:Area/Ncbi/Merge">000648</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Mixed influenza A and B infections complicate the detection of influenza viruses with altered sensitivities to neuraminidase inhibitors.</title><author><name sortKey="Mohr, Peter G" sort="Mohr, Peter G" uniqKey="Mohr P" first="Peter G" last="Mohr">Peter G. Mohr</name><affiliation wicri:level="1"><nlm:affiliation>CSIRO Livestock Industries, Australian Animal Health Laboratory (AAHL), Private Bag, Geelong VIC, Australia. peter.mohr@csiro.au</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>CSIRO Livestock Industries, Australian Animal Health Laboratory (AAHL), Private Bag, Geelong VIC</wicri:regionArea><wicri:noRegion>Geelong VIC</wicri:noRegion></affiliation></author><author><name sortKey="Geyer, Henriette" sort="Geyer, Henriette" uniqKey="Geyer H" first="Henriette" last="Geyer">Henriette Geyer</name></author><author><name sortKey="Mckimm Breschkin, Jennifer L" sort="Mckimm Breschkin, Jennifer L" uniqKey="Mckimm Breschkin J" first="Jennifer L" last="Mckimm-Breschkin">Jennifer L. Mckimm-Breschkin</name></author></analytic><series><title level="j">Antiviral research</title><idno type="eISSN">1872-9096</idno><imprint><date when="2011" type="published">2011</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antiviral Agents (pharmacology)</term><term>Antiviral Agents (therapeutic use)</term><term>Cell Line</term><term>Dogs</term><term>Drug Resistance, Viral</term><term>Enzyme Inhibitors (pharmacology)</term><term>Enzyme Inhibitors (therapeutic use)</term><term>Humans</term><term>Influenza A Virus, H2N2 Subtype (isolation & purification)</term><term>Influenza B virus (isolation & purification)</term><term>Influenza, Human (blood)</term><term>Influenza, Human (diagnosis)</term><term>Influenza, Human (virology)</term><term>Neuraminidase (antagonists & inhibitors)</term><term>Oseltamivir (pharmacology)</term><term>Oseltamivir (therapeutic use)</term><term>Zanamivir (pharmacology)</term><term>Zanamivir (therapeutic use)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Antienzymes (pharmacologie)</term><term>Antienzymes (usage thérapeutique)</term><term>Antiviraux (pharmacologie)</term><term>Antiviraux (usage thérapeutique)</term><term>Chiens</term><term>Grippe humaine (diagnostic)</term><term>Grippe humaine (sang)</term><term>Grippe humaine (virologie)</term><term>Humains</term><term>Lignée cellulaire</term><term>Oséltamivir (pharmacologie)</term><term>Oséltamivir (usage thérapeutique)</term><term>Résistance virale aux médicaments</term><term>Sialidase (antagonistes et inhibiteurs)</term><term>Sous-type H2N2 du virus de la grippe A (isolement et purification)</term><term>Virus influenza B (isolement et purification)</term><term>Zanamivir (pharmacologie)</term><term>Zanamivir (usage thérapeutique)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Neuraminidase</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term><term>Enzyme Inhibitors</term><term>Oseltamivir</term><term>Zanamivir</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term><term>Enzyme Inhibitors</term><term>Oseltamivir</term><term>Zanamivir</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Sialidase</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Influenza A Virus, H2N2 Subtype</term><term>Influenza B virus</term></keywords><keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Sous-type H2N2 du virus de la grippe A</term><term>Virus influenza B</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antienzymes</term><term>Antiviraux</term><term>Oséltamivir</term><term>Zanamivir</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antienzymes</term><term>Antiviraux</term><term>Oséltamivir</term><term>Zanamivir</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Cell Line</term><term>Dogs</term><term>Drug Resistance, Viral</term><term>Humans</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Chiens</term><term>Humains</term><term>Lignée cellulaire</term><term>Résistance virale aux médicaments</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Previously, three influenza A(H3N2) isolates with a reduced susceptibility to the neuraminidase inhibitors (NAIs) zanamivir and oseltamivir were identified during screening by the Neuraminidase Inhibitor Susceptibility Network (NISN). The isolates were from untreated patients from the first three years post licensure of the NAIs. We plaque-purified progeny from each of these isolates and determined the NAI sensitivity of each plaqued population. Sequencing and serology for each population revealed that the isolates contained a mix of wild type influenza A(H3N2) and influenza B. The NAI susceptibility reductions that had originally been reported were a consequence of influenza B neuraminidases that have lower relative NAI sensitivities, rather than being due to resistant influenza A(H3N2) viruses. Our study highlights the need to check for mixed influenza infections when isolates with potentially lower sensitivities to NAIs are identified.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21549758</PMID><DateCompleted><Year>2011</Year><Month>12</Month><Day>02</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-9096</ISSN><JournalIssue CitedMedium="Internet"><Volume>91</Volume><Issue>1</Issue><PubDate><Year>2011</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Antiviral research</Title><ISOAbbreviation>Antiviral Res.</ISOAbbreviation></Journal><ArticleTitle>Mixed influenza A and B infections complicate the detection of influenza viruses with altered sensitivities to neuraminidase inhibitors.</ArticleTitle><Pagination><MedlinePgn>20-2</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.antiviral.2011.04.010</ELocationID><Abstract><AbstractText>Previously, three influenza A(H3N2) isolates with a reduced susceptibility to the neuraminidase inhibitors (NAIs) zanamivir and oseltamivir were identified during screening by the Neuraminidase Inhibitor Susceptibility Network (NISN). The isolates were from untreated patients from the first three years post licensure of the NAIs. We plaque-purified progeny from each of these isolates and determined the NAI sensitivity of each plaqued population. Sequencing and serology for each population revealed that the isolates contained a mix of wild type influenza A(H3N2) and influenza B. The NAI susceptibility reductions that had originally been reported were a consequence of influenza B neuraminidases that have lower relative NAI sensitivities, rather than being due to resistant influenza A(H3N2) viruses. Our study highlights the need to check for mixed influenza infections when isolates with potentially lower sensitivities to NAIs are identified.</AbstractText><CopyrightInformation>Crown Copyright © 2011. Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mohr</LastName><ForeName>Peter G</ForeName><Initials>PG</Initials><AffiliationInfo><Affiliation>CSIRO Livestock Industries, Australian Animal Health Laboratory (AAHL), Private Bag, Geelong VIC, Australia. peter.mohr@csiro.au</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geyer</LastName><ForeName>Henriette</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>McKimm-Breschkin</LastName><ForeName>Jennifer L</ForeName><Initials>JL</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>04</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Antiviral Res</MedlineTA><NlmUniqueID>8109699</NlmUniqueID><ISSNLinking>0166-3542</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>20O93L6F9H</RegistryNumber><NameOfSubstance UI="D053139">Oseltamivir</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.2.1.18</RegistryNumber><NameOfSubstance UI="D009439">Neuraminidase</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6O3XI777I</RegistryNumber><NameOfSubstance UI="D053243">Zanamivir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004285" MajorTopicYN="N">Dogs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024882" MajorTopicYN="N">Drug Resistance, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053121" MajorTopicYN="N">Influenza A Virus, H2N2 Subtype</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="Y">isolation & purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009981" MajorTopicYN="N">Influenza B virus</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="Y">isolation & purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009439" MajorTopicYN="N">Neuraminidase</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053139" MajorTopicYN="N">Oseltamivir</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053243" MajorTopicYN="N">Zanamivir</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>09</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2011</Year><Month>03</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>04</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>5</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>5</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>12</Month><Day>13</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21549758</ArticleId><ArticleId IdType="pii">S0166-3542(11)00289-0</ArticleId><ArticleId IdType="doi">10.1016/j.antiviral.2011.04.010</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Australie</li></country></list><tree><noCountry><name sortKey="Geyer, Henriette" sort="Geyer, Henriette" uniqKey="Geyer H" first="Henriette" last="Geyer">Henriette Geyer</name><name sortKey="Mckimm Breschkin, Jennifer L" sort="Mckimm Breschkin, Jennifer L" uniqKey="Mckimm Breschkin J" first="Jennifer L" last="Mckimm-Breschkin">Jennifer L. Mckimm-Breschkin</name></noCountry><country name="Australie"><noRegion><name sortKey="Mohr, Peter G" sort="Mohr, Peter G" uniqKey="Mohr P" first="Peter G" last="Mohr">Peter G. Mohr</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000648 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000648 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:21549758
|texte= Mixed influenza A and B infections complicate the detection of influenza viruses with altered sensitivities to neuraminidase inhibitors.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:21549758" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a H2N2V1
| This area was generated with Dilib version V0.6.33. |  |